Welcome to the Office of Cancer Survivorship Program, DCCPS
The NCI Office of Cancer Survivorship (OCS) works to enhance the quality and length of survival of all persons diagnosed with cancer and to prevent, minimize, or manage adverse effects of cancer and its treatment.
In this Journal of Clinical Oncology publication, OCS Director Dr. Emily Tonorezos, Deputy Director Dr. Michelle Mollica, and coauthors discuss some commonly held beliefs related to cancer survivorship. Topics include shared care, provider preferences, and more.
National Survivorship Standards Subject Matter Expert Consensus Meetings: An Initiative of the President’s Cancer Cabinet
December 2023 – On December 12, 2023, from 2-3 p.m. ET, NCI, Veterans Affairs, & other HHS agencies are holding the third of three virtual meetings to develop national standards for survivorship care, including indicators for health system policy, processes, and evaluation. Register now to view this third session.
January 2024 – Join the NCI Office of Cancer Survivorship for this upcoming OCS Director’s Series webinar. On January 23, 2024, from 2-3 p.m. ET, Dr. Elizabeth Bouchard will present Understanding and Optimizing Social Support Across the Cancer Care Continuum. Register now.
February 2024 – The NCI Office of Cancer Survivorship is conducting a virtual event, Enhancing Capacity for Primary Care Research in Cancer Survivorship: A Workshop for Action, on February 28, 2024, to discuss research needs for addressing the intersection between primary care and cancer survivorship. Learn more and register.
About The Office of Cancer Survivorship
An individual is considered a cancer survivor from the time of diagnosis, through the balance of life. There are many types of survivors, including those living with cancer and those free of cancer. This term is meant to capture a population of those with a history of cancer rather than to provide a label that may or may not resonate with individuals.
OCS works to promote a better understanding of unique needs of the growing population of cancer survivors, and to enhance our ability to address them.
Featured Graph and Statistic
Researchers at the National Cancer Institute have estimated that 623,405 people in the United States were living with metastatic breast, prostate, lung, colorectal, or bladder cancer or metastatic melanoma as of 2018, and that number is expected to increase to 693,452 by the year 2025.